
ALPN Stock Forecast & Price Target
ALPN Analyst Ratings
Bulls say
Alpine Immune Sciences is showing promising results in their clinical trials of povetacicept for treating autoimmune diseases, with superior outcomes compared to current treatments and a strong potential for use in multiple indications. The recent positive data presented at a key nephrology conference and the significant increase in stock price reflect a growing confidence in the company's potential. With other ongoing studies in different indications, there is potential for even more growth and development for Alpine Immune Sciences.
Bears say
Alpine Immune Sciences is facing significant downside risks as its main pipeline candidates, ALPN-303/ALPN-101, may not prove to be efficacious and could face commercial challenges from current and future therapies. In addition, there is limited visibility on the progress and data of the acazicolcept program, leading to a modest outlook on its potential. The current treatment options for autoimmune and inflammatory diseases also have their own limitations, highlighting the potential risks and uncertainties surrounding Alpine's pipeline candidates.
This aggregate rating is based on analysts' research of Alpine Immune Sciences and is not a guaranteed prediction by Public.com or investment advice.
ALPN Analyst Forecast & Price Prediction
Start investing in ALPN
Order type
Buy in
Order amount
Est. shares
0 shares